Who are β-lactams or ciprofloxacin's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/lactams-or-ciprofloxacin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

β-lactams or ciprofloxacin — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

β-lactams or ciprofloxacin (β-lactams or ciprofloxacin) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antibiotic (β-lactam and fluoroquinolone). Area: Infectious Disease.

marketed Antibiotic (β-lactam and fluoroquinolone) Penicillin-binding proteins (β-lactams); DNA gyrase and topoisomerase IV (ciprofloxacin) Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

β-lactams or ciprofloxacin (β-lactams or ciprofloxacin) — University of Athens. β-lactams inhibit bacterial cell wall synthesis by binding penicillin-binding proteins, while ciprofloxacin inhibits bacterial DNA gyrase and topoisomerase IV to prevent DNA replication.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
β-lactams or ciprofloxacin TARGET	β-lactams or ciprofloxacin	University of Athens	marketed	Antibiotic (β-lactam and fluoroquinolone)	Penicillin-binding proteins (β-lactams); DNA gyrase and topoisomerase IV (ciprofloxacin)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antibiotic (β-lactam and fluoroquinolone) class)

University of Athens · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). β-lactams or ciprofloxacin — Competitive Intelligence Brief. https://druglandscape.com/ci/lactams-or-ciprofloxacin. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab